Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3CNS 3NET 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 7Neoplasms 7Thyroid Neoplasms 6Thyroid Cancer, Papillary 6Neoplasms by Site 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Thyroid Diseases 4Thoracic Neoplasms 4Sarcoma 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Lung Neoplasms 4Lung Diseases 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Colonic Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Salivary Gland Neoplasms 3Pheochromocytoma 3Paraganglioma 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Histologic Type 2Multiple Endocrine Neoplasia Type 1 2

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1belzutifan 1Lutetium-177 1Lutetium 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Pheochromocytoma × Endocrine × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡